Correlation Between Neurobo Pharmaceuticals and Orchestra BioMed

Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Orchestra BioMed at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Orchestra BioMed into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurobo Pharmaceuticals and Orchestra BioMed Holdings, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Orchestra BioMed and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Orchestra BioMed. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Orchestra BioMed.

Diversification Opportunities for Neurobo Pharmaceuticals and Orchestra BioMed

0.51

Correlation Coefficient

Neurobo Pharmaceuticals  Orchestra BioMed

Very weak diversification

The 3 months correlation between Neurobo and Orchestra is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Orchestra BioMed Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Orchestra BioMed Holdings and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Orchestra BioMed. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Orchestra BioMed Holdings has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Orchestra BioMed go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Orchestra BioMed

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Orchestra BioMed. But the stock apears to be less risky and, when comparing its historical volatility, Neurobo Pharmaceuticals is 1.33 times less risky than Orchestra BioMed. The stock trades about -0.03 of its potential returns per unit of risk. The Orchestra BioMed Holdings is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  551.00  in Orchestra BioMed Holdings on October 9, 2024 and sell it today you would earn a total of  15.00  from holding Orchestra BioMed Holdings or generate 2.72% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Neurobo Pharmaceuticals  vs.  Orchestra BioMed Holdings

Neurobo Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Orchestra BioMed Holdings

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Orchestra BioMed Holdings are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating forward indicators, Orchestra BioMed displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Neurobo Pharmaceuticals and Orchestra BioMed

The main advantage of trading using opposite Neurobo Pharmaceuticals and Orchestra BioMed positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Orchestra BioMed can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will offset losses from the drop in Orchestra BioMed's long position.

The idea behind Neurobo Pharmaceuticals and Orchestra BioMed Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.